Home India Department of Atomic Energy PARLIAMENT QUESTION: HOMI BHABHA CANCER HOSPITALS AND RADIOP...
Date: 2026-02-04 Category: Press Release State: Union Government Country: India

PARLIAMENT QUESTION: HOMI BHABHA CANCER HOSPITALS AND RADIOPHARMACEUTICAL PRODUCTION CENTRES

Issued by Department of Atomic Energy · Not Applicable

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

**Executive Summary** The document is a response to a Parliament question regarding Homi Bhabha Cancer Hospitals and Radiopharmaceutical Production Centres, submitted on February 4, 2026. It outlines the expansion of the Tata Memorial Centre (TMC) to provide comprehensive cancer care in multiple states by establishing 11 Hospitals/Institutions. It also details activities in Odisha regarding irradiation facilities, rare earth element (REE) resources, and production of high-purity materials, along with a future facility targeted for completion by March 31, 2027. **Key Points / Main Content** * **Hospital Infrastructure and Capacity:** * Tata Memorial Centre (TMC) is expanding cancer care by establishing 11 hospitals and institutions across seven states. * The document provides data on the name of the hospitals, commissioning date, number of beds, number of patients registered in 2025, and number of surgeries performed in 2025. * The document shows the Platinum Jubilee Block in Mumbai is expected to be completed by 31/03/2027. * The Integrated Centre for Treatment, Research, and Education in Cancer (ICTREC) in Khopoli, Maharashtra is expected to be completed by 27/06/2026. * The Homi Bhabha Cancer Hospital in Bhubaneswar, Odisha is expected to be completed by 07/05/2026. * **Radiopharmaceutical Production and Material Development:** * TMC has created a facility at Khopoli, leveraging the Indian system of medicine for drug discovery. * BARC has developed a Certified Reference Material (FC-CRM) for rare earth elements (REEs) for exploration, extraction, and process control in REE ore mining. * BARC produces high-purity gallium, indium, and germanium, vital for semiconductors and radiation detectors. * BARC also produces requisite quality lutetium for radiopharmaceutical applications through isotope enrichment. * **Odisha Specific Initiatives:** * A 200-bed state-of-the-art cancer hospital and research centre is being established at the NISER Campus, Jatni (Khurda district), Odisha. * There are two Gamma Irradiation Chamber units in Odisha: GC-5000 in NISER and a Blood Irradiator in “IMS & SUM Hospital”. * BARC is jointly working with Atomic Minerals Directorate for Exploration and Research (AMDER) to explore REEs in large deposits. * **Technological Advancements:** * The indigenously developed technologies related to REEs CRM are likely to reduce the dependency on imports, in line with the Atmanirbhar Bharat initiative. * The document highlights that these materials are vital for major technology intensive sectors such as renewable energy, healthcare, electronics, and radiation detectors. **Impact Analysis** **Stakeholder: Patients Requiring Cancer Care** * **Impact:** Expanded access to cancer treatment facilities and advanced radiopharmaceutical applications. * **Action Required:** Be aware of the availability of new and expanding cancer treatment facilities. **Stakeholder: Tata Memorial Centre (TMC)** * **Impact:** Expansion of infrastructure and capabilities across multiple states. * **Action Required:** Continue the expansion efforts, including construction, commissioning of new facilities, and staffing. **Stakeholder: Bhabha Atomic Research Centre (BARC)** * **Impact:** Increased responsibility in developing and providing critical materials for cancer treatment. * **Action Required:** Continue research and development in REEs, radiopharmaceuticals, and high-purity materials. **Stakeholder: Industries and Hospitals across the country, including Odisha** * **Impact:** Access to CRM and lutetium based radiopharmaceutical development. * **Action Required:** Utilize the developed resources for radiopharmaceutical applications. **Stakeholder: Indian system of medicine practitioners** * **Impact:** More opportunity for research. * **Action Required:** Support and take part in the research efforts with TMC, based on the Indian system of medicine.

Key Entities Referenced

Department of Atomic Energy: The administrative department responsible for the listed cancer hospitals and radiopharmaceutical production centres. Homi Bhabha Cancer Hospitals: A network of cancer hospitals established across multiple states in India. Tata Memorial Centre (TMC): Organization under the administrative control of the Department of Atomic Energy, expanding cancer care facilities across seven states. Odisha: State with specific references to irradiation facilities and REE exploration. Bhabha Atomic Research Centre (BARC): Institute involved in research and development of technologies for nuclear and medical applications, including REE exploration.
Official Source Record View Original Source →
See Full Document Text
Department of Atomic Energy PARLIAMENT QUESTION: HOMI BHABHA CANCER HOSPITALS AND RADIOPHARMACEUTICAL PRODUCTION CENTRES Posted On: 04 FEB 2026 6:23PM by PIB Delhi No. of No. Sr. Name of the City, State Date of Beds Patient surger Hospital commissioning Registered perfor No. in 2025 in 2025 1 Tata Memorial Mumbai, 1941 650 35705 43208 Hospital Maharashtra Advanced Navi Mumbai, 2 Centre Maharashtra 2002 500 8970 12588 for Treatment, Research and Education in Cancer (ACTREC) Mahamana Pt. Varanasi, 3 Madan Uttar Pradesh 19/02/2019 394 25047 4188 Mohan Malaviya Cancer Centre (MPMMCC) at Varanasi4 Homi Varanasi, 01/05/2018 189 2684 556 Bhabha Uttar Pradesh Cancer Hospital 5 Homi Visakhapatnam, 11/05/2023 210 9751 4581 Bhabha Andhra Pradesh Cancer Hospital & Research Centre 6 Homi New 24/08/2022 300 10107 4807 Bhabha Chandigarh, Cancer Punjab Hospital & Research Centre 7 Homi Sangrur, Punjab 20/01/2015 150 7796 1963 Bhabha Cancer Hospital 8 Dr. B. Guwahati, Assam 27/11/2017 312 9810 4273 Borooah Cancer Institute (BBCI) 9 Homi Muzaffarpur, 30/04/2025 107 7526 1212 Bhabha Bihar Cancer Hospital and Research Centre 10 Platinum Jubilee Mumbai, Expected 583 -- -- Block Maharashtra 31/03/2027Integrated Khopoli, Expected Centre for Raighad, 27/06/2026 11 75 -- -- Treatment, Maharashtra Research, and Education in Cancer (ICTREC) 12 Homi Bhubaneswar, Expected 200 -- -- Bhabha Odisha 07/05/2026 Cancer Hospital Tata Memorial Centre (TMC) under the Administrative control of Department of Atomic Energy expanded in seven states by establishing 11 Hospital/Institutions to provide the comprehensive cancer care at Mumbai, Kharghar-New Mumbai, Punjab, Varanasi, Vizag, Muzaffarupur and Guwahati. TMC created the facility at Khopoli by tapping Indian system of medicine for drug discovery and for cheaper and less side effective drugs. Promotion of Indian and Traditional knowledge of Medicine. Cultivation and Conservation of Medicinal plants unique to India and a 200-bed state-of-the-art cancer hospital and research centre is being established at the NISER Campus, Jatni (Khurda district), Odisha. The current status and the utilization are as follows: a. There is no irradiation facility established by DAE for sterilisation of medical products in Odisha. There are two Gamma Irradiation Chamber unit in Odisha i. GC-5000 installed in “National Institute of Science Education and Research (NISER), Bhubaneswar, Odisha. ii. Blood Irradiator in “IMS & SUM Hospital”, Bhubaneswar, Odisha. b. Ferrocarbonatite (FC) is a proven source for REEs explored in large deposits in India. Bhabha Atomic Research Centre (BARC), jointly with Atomic Minerals Directorate for Exploration and Research (AMDER), has prepared Certified Reference Material (FC- CRM) for rare earth element (REE) required for development and validation of analytical methods, calibration of instruments and quality control. It certifies 13 REEs (Ce, Dy, Er, Eu, Gd, La, Nd, Pr, Sc, Sm, Tb, Y and Yb) and 6 major elements (Al, Ca, Fe, Mg, Mn and P) and is useful in exploration, extraction and process control in REE ore mining. The CRM is the 4th such CRM in the world and first in India. BARC is producing high-purity gallium, indium, and germanium which is vital for use in semiconductors and radiation detectors to support its nuclear power programme. Further, requisite quality lutetium for radiopharmaceutical applications is also produced through isotope enrichment route. These CRM and lutetium based radiopharmaceutical development can be used by industries and hospitals respectively across the country including Odisha. c. These indigenously developed technologies related to REEs CRM required for exploration, extraction and process control in REE ore mining, production of radioisotope of requisite quality for medical applications especially in cancer care and production of high purity gallium, indium, and germanium are likely to reduce the dependency on imports in line with the Atmanirbhar Bharat initiative. These materials are vital for major technology intensive sectors such as renewable energy,healthcare sector, electronics, radiation detectors for self-reliance in nuclear, healthcare and industrial sector in the country including the state of Odisha. Presently, BARC does not have project proposal in the tribal and aspirational district in Odisha. This Information was submitted by The Minister Of State For Prime Minister’s Office Dr. Jitendra Singh in Lok Sabha on 4th February 2026. ***** NKR/JP (Release ID: 2223303) Visitor Counter : 80 Read this release in: Urdu , ही , Marathi

Continue your research